Browse > Article
http://dx.doi.org/10.9758/cpn.2018.16.4.497

Clinical Usefulness of Aripiprazole Treatment in a Girl with Prader-Willi Syndrome and Psychosis  

Briegel, Wolfgang (Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Leopoldina Hospital)
Publication Information
Clinical Psychopharmacology and Neuroscience / v.16, no.4, 2018 , pp. 497-500 More about this Journal
Abstract
Prader-Willi syndrome (PWS) is a quite rare multi-systemic genetic disorder strongly associated with psychiatric illness in adults, especially psychosis. This report presents a 16-year-old female with PWS and symptoms of brief psychotic disorder with a complete resolution of symptoms under aripiprazole medication. However, an exacerbation occurred after aripiprazole reduction. Apart from a weight gain of about 2 kg over the course of two years, no adverse effects could be found. This first report on the use of aripiprazole in a subject with PWS and psychosis suggests that aripiprazole might be a promising treatment approach in this distinct group of patients.
Keywords
Prader-Willi syndrome; Aripiprazole; Psychosis; Adolescent; Case reports;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cassidy SB, Driscoll DJ. Prader-Willi syndrome. Eur J Hum Genet 2009;17:3-13.   DOI
2 Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocrinol Invest 2015;38:1249-1263.   DOI
3 Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi syndrome. 1998 Oct 6 [updated 2016 Feb 4, cited 2017 Nov 10]. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. $GeneReviews^{(R)}$ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1330/
4 Ho AY, Dimitropoulos A. Clinical management of behavioral characteristics of Prader-Willi syndrome. Neuropsychiatr Dis Treat 2010;6:107-118.
5 Sinnema M, Boer H, Collin P, Maaskant MA, van Roozendaal KE, Schrander-Stumpel CT, et al. Psychiatric illness in a cohort of adults with Prader-Willi syndrome. Res Dev Disabil 2011;32:1729-1735.   DOI
6 Bonnot O, Cohen D, Thuilleaux D, Consoli A, Cabal S, Tauber M. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature. Eur J Pediatr 2016;175:9-18.
7 Benjamin E, Buot-Smith T. Naltrexone and fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:870-873.   DOI
8 Akca OF, Yilmaz S. Aripiprazole in the treatment of obsessive compulsive disorder and aggressive behaviors in a child with Prader Silli syndrome: a case report. J Clin Psychopharmacol 2016;36:526-528.   DOI
9 Herguner S, Mukaddes NM. Psychosis associated with fluoxetine in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 2007;46:944-945.   DOI
10 Kohn Y, Weizman A, Apter A. Aggravation of food-related behavior in an adolescent with Prader-Willi syndrome treated with fluvoxamine and fluoxetine. Int J Eat Disord 2001;30:113-117.   DOI
11 Kaufman AS, Kaufman NL. Kaufman assessment battery for children K-ABC. 8th ed. German version by Melchers P and Preuss U. Frankfurt am Main:Pearson Assessment;2009.
12 Dech B, Budow L. The use of fluoxetine in an adolescent with Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry 1991;30:298-302.   DOI
13 Araki S, Ohji T, Shiota N, Dobashi K, Shimono M, Shirahata A. Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome. Pediatr Int 2010;52:e1-e3.   DOI
14 Durst R, Rubin-Jabotinsky K, Raskin S, Katz G, Zislin J. Risperidone in treating behavioural disturbances of Prader-Willi syndrome. Acta Psychiatr Scand 2000;102:461-465.   DOI
15 Yang L, Zhan GD, Ding JJ, Wang HJ, Ma D, Huang GY, et al. Psychiatric illness and intellectual disability in the Prader-Willi syndrome with different molecular defects--a meta analysis. PLoS One 2013;8:e72640.   DOI
16 Lo ST, Collin PJ, Hokken-Koelega AC. Psychiatric disorders in children with Prader-Willi syndrome-Results of a 2-year longitudinal study. Am J Med Genet A 2015;167A:983-991.
17 Briegel W. Neuropsychiatric aspects of Prader-Willi syndrome-a review. Z Kinder Jugendpsychiatr Psychother 2017;14:1-8.
18 Ventriglio A, Gentile A, Stella E, Bellomo A. Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci 2015;9:297.
19 Safer DJ, Calarge CA, Safer AM. Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol 2013;23:282-289.   DOI
20 Soni S, Whittington J, Holland AJ, Webb T, Maina EN, Boer H, et al. The phenomenology and diagnosis of psychiatric illness in people with Prader-Willi syndrome. Psychol Med 2008;38:1505-1514.   DOI